Omnitrope Shortage Update: What Patients Need to Know in 2026

The growth hormone market has experienced significant turbulence since late 2022, with multiple somatropin brands reporting supply disruptions, production scale-ups, and even product discontinuations. If you take Omnitrope — or are being switched to Omnitrope from another brand — here is the most current information on its availability heading into 2026.

Is Omnitrope Currently in Shortage? (2026 Update)

As of December 2025, Omnitrope is NOT listed on the FDA Drug Shortage Database. The American Society of Health-System Pharmacists (ASHP) confirmed that Sandoz has all marketed presentations of Omnitrope available, including the 5 mg/1.5 mL and 10 mg/1.5 mL cartridges. This is encouraging news for patients who depend on Omnitrope for growth hormone replacement therapy.

However, "not in shortage" does not mean "easy to get." Specialty pharmacy distribution requirements, prior authorization delays, and insurance formulary gatekeeping continue to create meaningful barriers for patients trying to fill their prescriptions.

What Happened With the Broader Somatropin Shortage?

The broader somatropin class hit a significant supply crisis starting in late 2022. Key developments included:

• Norditropin shortage (2022–2023): Novo Nordisk faced severe supply constraints, leading many patients to be switched to alternative brands.
• Nutropin AQ NuSpin shortage (2023–2025): Genentech reported supply constraints beginning August 2023, driven by "a significant and sustained increase in demand due to fluctuations in supply across several growth hormone manufacturers." The 30 mg/3 mL NuSpin was ultimately discontinued in late 2025.
• Genotropin production ramp: Pfizer tripled Genotropin production in 2023 (3.5x the 2022 output) to help address the broader market shortage.
• Demand surge: As patients were switched from shortage brands to available ones, demand for Omnitrope increased, leading to localized inventory strain at individual pharmacies — even as national supply remained adequate.

Why Do Patients Still Struggle to Get Omnitrope Even Without a Shortage?

Several structural factors make Omnitrope difficult to access even during periods of adequate national supply:

• Specialty pharmacy-only distribution: Omnitrope requires cold-chain storage and is not stocked by most retail pharmacies. Patients must use designated specialty pharmacies, which may have variable inventory.
• Prior authorization: Every commercial insurance plan and Medicare Part D requires prior authorization — and renewals — creating recurring gaps in access.
• Cost barriers: A single 5 mg/1.5 mL Omnitrope cartridge costs over $650 at retail, putting it out of reach for uninsured patients without assistance programs.

What Should Omnitrope Patients Do in 2026?

Here are the most important steps to protect your Omnitrope supply in 2026:

1. Renew your prior authorization early. Don't wait until your PA expires. Most insurers require 2–4 weeks for renewal. Start the process 30 days before expiration.
2. Build a small buffer supply. If your insurer allows early refills (often after 75–80% of a fill is used), refill before you're fully out.
3. Know your bridge supply option. Through Sandoz's OmniSource program, commercially insured patients can receive free Omnitrope for up to 1 year if insurance authorization is delayed more than 10 business days. Call 877-456-6794.
4. Have a backup brand in mind. Talk to your endocrinologist now about which alternative somatropin brand (Norditropin, Genotropin, Humatrope) you could switch to if Omnitrope becomes unavailable. Don't wait for a crisis to have this conversation.
5. Use medfinder if you can't find it locally. medfinder calls pharmacies near you to find which ones have Omnitrope in stock — so you don't have to spend hours on hold.

How to Stay Informed About Omnitrope Availability

The FDA Drug Shortage Database (accessdata.fda.gov) and ASHP's Drug Shortage Resource Center are the most authoritative sources for real-time shortage status. Check these before making any medication changes. For a provider-focused view of the Omnitrope supply situation, see: Omnitrope shortage: What providers need to know in 2026.

The Bottom Line

Omnitrope is not in a formal shortage as of 2026 — but the broader growth hormone market remains volatile, and structural access barriers persist. The best defense is proactive refill management, a solid relationship with a specialty pharmacy, and a contingency plan with your endocrinologist. If you're struggling to fill your prescription today, medfinder can help you locate a pharmacy that has it in stock near you.